Beranda › Leukemia Mieloid Akut › California › Orange
Uji klinis Leukemia Mieloid Akut di Orange, CA
13 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Orange (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Menerima pesertaFase 2
- UCI Health Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Menerima pesertaFase 3
- Children's Hospital of Orange County, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Menerima pesertaFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Menerima pesertaFase 3
- Children's Hospital of Orange County Main Campus - Orange, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Menerima pesertaFase 3
- University of California, Irvine, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Menerima pesertaFase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Menerima pesertaFase 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Menerima pesertaStudi observasional
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Menerima pesertaFase 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Menerima pesertaFase 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Uji klinis Leukemia Mieloid Akut di kota lain
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Studi lain di Orange
- Kanker Paru Non-Sel Kecil25 studi
- Kanker Metastatik20 studi
- Kanker Kolorektal16 studi
- Kanker Ovarium16 studi
- Kanker Pankreas15 studi
- Melanoma14 studi
- Kanker Hati (Karsinoma Hepatoseluler)14 studi
- Kanker Payudara14 studi
- Kanker Paru14 studi
- Kanker Prostat14 studi
- Kanker Lambung13 studi
- Kanker (semua jenis)13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.